In multiple sclerosis (MS), a person's immune system attacks the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord (central nervous system). MS disease-modifying ...

A significant portion of patients with multiple sclerosis (MS) can achieve a stable disease state when treated with modern disease-modifying therapy (DMT), especially when started early in the disease ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

The majority of infections in multiple sclerosis (MS) are reported in non-neurology practices, according to study results presented at the European Committee for Treatment and Research in Multiple ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

Women with multiple sclerosis (MS) are significantly less likely than men to be treated with disease-modifying therapies (DMTs) and highly effective DMTs (HE-DMTs), a new study showed. At comparable ...

Discover the latest insights on pediatric-onset multiple sclerosis, emphasizing early intervention and high-efficacy therapies for improved outcomes in children. The diagnostic landscape for POMS has ...

Kesimpta is a medication used to treat relapsing forms of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Kesimpta comes as a solution inside single-dose prefilled injection pens or ...